Translation and implementation of PeptiQuant Plus Human Plasma BAK-270

The large-scale quantitation of proteins in biomarker screening exercises is being increasingly employed in the proteomics field to discover, and ultimately validate, disease indicators. These evaluations are commonly performed in blood plasma samples by liquid chromatography (LC)-tandem mass spectrometry (MS/MS). To assist researchers developments and applications, Cambridge Isotope Laboratories, Inc. (CIL) supplies PeptiQuant™ Plus biomarker assessment kits (BAKs) for plasma protein interrogations by bottom-up LC-MS/MS. As part of a joint collaboration with CIL and Université de Montpellier, the latest BAK-270 was translated to a Shimadzu LC-MS platform at the Université de Montpellier. This application note outlines that process, its results, and an overview into its clinical application at Montpellier Hospital.